Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
|Articles|June 16, 2009
Oncology NEWS International
- Oncology NEWS International Vol 18 No 6
- Volume 18
- Issue 6
Foundation launches financial aid for brain cancer patients
The HealthWell Foundation has launched a program to assist patients diagnosed with glioblastoma multiforme and anaplastic astrocytoma.
Advertisement
The HealthWell Foundation has launched a program to assist patients diagnosed with glioblastoma multiforme and anaplastic astrocytoma.
By applying to the program, patients can receive assistance with prescription drug copays, coinsurance, and deductibles, according to the foundation, a non-profit organization that provides financial assistance to underinsured patients with chronic or life-threatening diseases.
Information on applying for financial assistance can be found at www.healthwellfoundation.org.
Articles in this issue
over 17 years ago
ADT in prostate ca increases risk of bone and heart complicationsover 17 years ago
Abraxis backs SPARC as prognostic biomarkerover 17 years ago
ALK-1 receptor: New target in angiogenesisover 17 years ago
Abraxane prolongs PFS in metastatic diseaseover 17 years ago
SAVI applicator removes obstacles associated with brachytherapyover 17 years ago
Mistrust, costs reduce breast cancer screening among minoritiesover 17 years ago
Oral chemotherapy poses more challenges for cancer communityover 17 years ago
CMS nixes CT colonography screeningover 17 years ago
New ultrasound strategy helps pinpoint prostate tumorsAdvertisement
Related to this article
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
4
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
5